After Another NICE No, Will It Be Third Time Lucky For J&J's Spravato?
Market Access Process For Mental Health Product Proves Challenging
The healthcare giant's nasal spray for hard-to-treat depression has been rejected for use on the UK's NHS for a second time because of uncertainty over cost, but comments on this consultation could result in a change of fortunes for the potential blockbuster.
You may also be interested in...
The US FDA approved the esketamine nasal spray for adults with major depressive disorder with suicidal ideation or behavior, following its initial approval in 2019 for treatment-resistant depression.
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.